Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02059278 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
A Phase 3 study, sponsored by Nephron Pharmaceuticals Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 335
- Enrollment target
NCT02059278: Completed Phase 3 study, sponsored by Nephron Pharmaceuticals Corporation.
NCT02059278 is a Phase 3 study that has completed, run by Nephron Pharmaceuticals Corporation. The registered enrollment target is 335 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (57% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02059278, a Phase 3 study, has completed, sponsored by Nephron Pharmaceuticals Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 335 participants
- Enrollment target
Study Summary
This is a Phase 3 study to evaluate the safety and efficacy of T-2345 dosed to one of both eyes once daily for 84 days compared to Xalatan dosed to one of both eyes once daily for 84 days in patients with elevated eye pressure.
Primary Outcome
Evaluation of intraocular pressure using Goldmann applanation tonometry. Primary outcome was the between group difference in the change from baseline in IOP at each of 9 assessment points. Equivalence was achieved if the 95% Confidence Intervals were within 1.5 mmHg at all 9 time points
Interventions
- DRUG Xalatan
- DRUG T-2345
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 335 participants |
| Start Date | 2014-01 |
| Est. Completion | 2015-01 |
| Phase | Phase 3 |
What the finished NCT02059278 record still lists
NCT02059278 is an interventional study that assigns participants to a tested intervention. The registered 335 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (57% lower).
The record links to 0 conditions, and to 2 interventions - of which Xalatan is the first listed.
NCT02059278 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02059278 about?
NCT02059278 is a clinical study titled "Safety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension". This is a Phase 3 study to evaluate the safety and efficacy of T-2345 dosed to one of both eyes once daily for 84 days compared to Xalatan dosed to one of both eyes once daily for 84 days in patients with elevated eye pressure.
What is the current status of trial NCT02059278?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 335 participants. The study started on 2014-01. Estimated completion is 2015-01.
What interventions are being tested in trial NCT02059278?
The interventions under investigation include: Xalatan (DRUG), T-2345 (DRUG).
Who is sponsoring clinical trial NCT02059278?
This trial is sponsored by Nephron Pharmaceuticals Corporation, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02059278's enrollment target sits among peer trials
335 1061st of 2000 higher than 940 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04134754 · 335 participants · NA
Carbon Dioxide (CO2) Chemosensitivity and SUDEP
- NCT05554406 · 335 participants · Phase 2
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
- NCT06183437 · 335 participants · Phase 4
The STOP-MED CTRCD Trial
- NCT06885177 · 335 participants · NA
TECTONIC CAD IVL IDE Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia